SCHEMBL3309377

SCHEMBL3309377

CCOC(=O)C1CCC=CCCCCN(C)C(=O)C2CC(Oc3cc(-c4ccc(OC)cc4)nc(OC)n3)CC2C(=O)N1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CTSB P07858 1/20 0.41
▸ CTSS P25774 1/20 0.35
▸ THRB P10828 1/20 0.35
▸ MAPT P10636 5/20 0.34
▸ ALDH1A1 P00352 5/20 0.34
▸ USP2 O75604 1/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ HSP90AA1 P07900 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ CYP2C9 P11712 1/20 0.34
▸ TSHR P16473 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ HSD17B10 Q99714 1/20 0.34
▸ POLB P06746 3/20 0.33
▸ RAB9A P51151 4/20 0.32
▸ NPC1 O15118 3/20 0.32
▸ KDM4E B2RXH2 4/20 0.32
▸ L3MBTL1 Q9Y468 1/20 0.32
▸ HPGD P15428 1/20 0.31
▸ LMNA P02545 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3309557 0.94 CTSB (0.43) CTSBCTSSMAPTALDH1A1CYP1A2
SCHEMBL3315190 0.91 CTSB (0.45) CTSBCTSSMAPTALDH1A1HSD17B10
SCHEMBL3313061 0.90 CTSB (0.35) CTSBCTSSALDH1A1
SCHEMBL3306838 0.87 CTSB (0.34) CTSBCTSS
SCHEMBL3307886 0.86 CTSB (0.42) CTSBMAPTALDH1A1CYP3A4CYP2C9
SCHEMBL3309948 0.85 CTSB (0.45) CTSBCTSSMAPTTSHRPOLB
SCHEMBL3309641 0.84 CTSB (0.45) CTSBCTSSTHRBMAPTALDH1A1
SCHEMBL3039920 0.83 CTSB (0.61) CTSBCTSSMAPTALDH1A1POLB
SCHEMBL13330929 0.82 CTSB (0.54) CTSBCTSSMAPTRAB9ANPC1
SCHEMBL3309369 0.82 CTSB (0.54) CTSBCTSSMAPTRAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8937080-B2 Pyrimidine substituted macrocyclic HCV inhibitors MEDIVIR AB (SE) 2015-01-20 — — US disclosed
US-20100113440-A1 PYRIMIDINE SUBSTITUTED MACROCYCLIC HCV INHIBITORS TIBOTEC PHARMACEUTICALS, LTD. (IE) 2010-05-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113440-A1 PYRIMIDINE SUBSTITUTED MACROCYCLIC HCV INHIBITORS NUDT1, PNP, SLC28A1 CTSB 2141/4885CTSS 1936/4885THRB 3835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback